Silo Pharma’s PTSD Program Aligns With Federal Push To Fast‑Track Psychedelic Therapies

Silo Pharma (NASDAQ: SILO) is highlighting progress in its post‑traumatic stress disorder (PTSD) program as U.S. regulators move faster on psychedelic‑based mental health treatments. A recent executive order from President Donald Trump directs federal agencies to speed research and patient access for psychedelic compounds in conditions like PTSD, depression, and anxiety, and the FDA has begun granting priority pathways to several psychedelic and psychedelic‑adjacent therapies.

What SPC‑15 is and how it works

Silo’s lead program, SPC‑15, is designed as an intranasal, prophylactic treatment that targets PTSD and stress‑related disorders. The drug is a novel serotonin 4 (5‑HT4) receptor agonist delivered through a nose‑to‑brain device, which aims to move medicine quickly into the central nervous system and support convenient use. Silo is developing SPC‑15 under the FDA’s 505(b)(2) pathway, which can let companies reference existing data on related drugs and may allow a more streamlined clinical timeline if everything goes as planned.

Policy momentum and why it matters for Silo

The federal government is now more openly encouraging research into psychedelic and psychedelic‑inspired therapies, including mechanisms to compress review times for high‑priority mental health drugs. This shift does not guarantee SPC‑15 any specific designation, but it does create a more supportive backdrop for Silo as it prepares to engage with the FDA on an Investigational New Drug (IND) application and moves the program toward formal clinical trials. Silo’s CEO has said the company believes its PTSD program and broader central nervous system pipeline are well positioned to benefit from this friendlier regulatory and clinical environment.

Broader pipeline and financial context

Beyond SPC‑15, Silo’s pipeline includes SP‑26 for fibromyalgia and chronic pain, as well as early‑stage work that targets conditions such as Alzheimer’s disease. The company remains in the development stage, meaning it does not yet generate commercial drug revenue, but it reports having more cash than debt on its balance sheet, which can help fund near‑term research steps. Shares of SILO have been volatile, with the stock up more than 50% year‑to‑date amid rising interest in psychedelic‑related names and the recent policy announcements.